De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2-and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET

Harbeck, Nadia; Gluz, Oleg; Christgen, Matthias; Kates, Ronald Ernest; Braun, Michael; Kueemmel, Sherko; Schumacher, Claudia; Potenberg, Jochem; Kraemer, Stefan; Kleine-Tebbe, Anke; Augustin, Doris; Aktas, Bahriye; Forstbauer, Helmut; Tio, Joke; von Schumann, Raquel; Liedtke, Cornelia; Grischke, Eva-Maria; Schumacher, Johannes; Wuerstlein, Rachel; Kreipe, Hans Heinrich; Nitz, Ulrike Anneliese

De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2-and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET

DSpace Repositorium (Manakin basiert)

Einloggen

« zurück

Zur Kurzanzeige

dc.contributor.author	Grischke, Eva-Maria
dc.date.accessioned	2019-05-07T14:06:47Z
dc.date.available	2019-05-07T14:06:47Z
dc.date.issued	2017
dc.identifier.issn	1527-7755
dc.identifier.uri	http://hdl.handle.net/10900/88445
dc.language.iso	en	de_DE
dc.publisher	Amer Soc Clinical Oncology	de_DE
dc.relation.uri	http://dx.doi.org/10.1200/JCO.2016.71.9815	de_DE
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject.ddc	610	de_DE
dc.title	De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2-and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET	de_DE
dc.type	Article	de_DE
utue.quellen.id	20190131163842_01440
utue.publikation.seiten	3046-	de_DE
utue.personen.roh	Harbeck, Nadia
utue.personen.roh	Gluz, Oleg
utue.personen.roh	Christgen, Matthias
utue.personen.roh	Kates, Ronald Ernest
utue.personen.roh	Braun, Michael
utue.personen.roh	Kueemmel, Sherko
utue.personen.roh	Schumacher, Claudia
utue.personen.roh	Potenberg, Jochem
utue.personen.roh	Kraemer, Stefan
utue.personen.roh	Kleine-Tebbe, Anke
utue.personen.roh	Augustin, Doris
utue.personen.roh	Aktas, Bahriye
utue.personen.roh	Forstbauer, Helmut
utue.personen.roh	Tio, Joke
utue.personen.roh	von Schumann, Raquel
utue.personen.roh	Liedtke, Cornelia
utue.personen.roh	Grischke, Eva-Maria
utue.personen.roh	Schumacher, Johannes
utue.personen.roh	Wuerstlein, Rachel
utue.personen.roh	Kreipe, Hans Heinrich
utue.personen.roh	Nitz, Ulrike Anneliese
dcterms.isPartOf.ZSTitelID	Journal of Clinical Oncology	de_DE
dcterms.isPartOf.ZS-Issue	26	de_DE
dcterms.isPartOf.ZS-Volume	35	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE